Zizi brings 29 years of Bio-Pharmaceutical and Clinical Research industry experience. Her background has included working with small and large bio-pharma companies to identify potential challenges and solutions to ensure successful early and late phase clinical operational strategies – and ultimately, shorten clinical development timelines.
Early Phase Clinical Development in particular requires integrated scientific strategy as well as nimble operations. Zizi has worked with sponsors to adapt a distinct Early Phase Model to help them successfully operationalize their studies and meet their development goals.
She has helped to shepherd compounds’ and devices from concept to launch across therapeutic areas, as well as successfully operationalizing clinical studies with a particular expertise in Rare Diseases, CNS, and Oncology/Hematology.
She is the Head of PAREXEL’s Rare Disease Initiative including its Center of Excellence, a dedicated cross functional team that addresses strategic, operational and medical challenges faced in managing rare disease studies. Some of her previous employers prior to PAREXEL include PPD, McKesson and Glaxo Smith Kline among others. Her functions have included Strategy Development, Consulting , Clinical Operations Oversight, Clinical Research, Sales and Marketing.
Her educational background includes an MS in Biotechnology from the University College London, University of London, and an MBA from Chapman University, California. She is PMP® certified and Lean Six Sigma trained – all providing a strong business perspective as well as clinical operations expertise.
Zizi is passionate about supporting Rare Disease causes and actively participates in the Rare Disease community.